← All UbiTiter issuesUbiTiter Issue #8
In Vivo Antibody Click, Masked Cytokines, and Antibody Developability at Scale
Conditional and combinatorial targeting dominates this week: drugs assembled or unmasked only where two signals coincide, and large-scale structural data correcting the design rules underneath all of it.
- antibody-drug conjugates
- bioorthogonal click chemistry
- masked cytokines
- VHH / nanobody
- bispecific antibodies
- antibody developability
- N-linked glycosylation
- quantitative systems pharmacology
The field
This Week in Biologics
Paper 1 · Nature
Modular in vivo antibody–ADC click to reverse drug resistance in tumours
Sequentially dosed antibody-TCO and ADC-tetrazine conjugates ligate inside the tumor via click chemistry, lifting trastuzumab uptake in HER2-ultralow tumors 3.2-fold and driving complete remissions in models that resist conventional ADCs.
Core finding
A bioorthogonal ligation strategy administers an antibody carrying a trans-cyclooctene handle and an ADC carrying a tetrazine handle separately, letting them couple in vivo through an inverse-electron-demand Diels-Alder reaction that completes in under 30 minutes. In HER2-ultralow tumors, click conditions raised trastuzumab accumulation 3.2-fold (31.63 versus 11.90 %ID/g), produced 100% complete remission in HER2-positive NCIN87 tumors, 50% complete response in HER2-low immunocompetent models, and responses in 5 of 9 previously T-DXd-refractory tumors that had upregulated EGFR.
What's novel
It achieves dual-antigen engagement without engineering a bispecific. Pairing FDA-approved antibodies (trastuzumab, panitumumab, pertuzumab) and approved payloads (T-DXd, T-DM1) through modular click handles lets a two-component system address antigen heterogeneity, and site-specific conjugation on Fc glycans cut hepatic accumulation two-fold versus random lysine labeling.
Limitations
Simultaneous systemic and tumor-site click reactions make it hard to cleanly separate receptor-mediated uptake from antibody clustering or altered pharmacokinetics; work is preclinical only, DXd-associated lung toxicity is unaddressed, and the proof of concept is confined to the HER2/EGFR axis.
In context
This builds on a decade of bioorthogonal pretargeting work, mostly used for imaging, and repurposes it as an in-tumor drug-assembly step. It offers a lower-engineering-cost route to the multi-target coverage that bispecific ADCs pursue, and slots alongside the field's growing interest in overcoming antigen heterogeneity and acquired ADC resistance.
Paper 2 · mAbs
Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate
A dual-specificity switch arm keeps IL-12 masked in circulation and unveils it only where the tumor matrix antigen FN-EDB competes it off, a trans-activation logic gate tuned with a QSP model and validated in cell assays.
Core finding
Switch-IL-12 is a reversible antibody format built from a switch arm that competitively binds either a tethered single-chain IL-12 or the pan-tumor matrix antigen Fibronectin extra-domain B (FN-EDB), plus a separate FN-EDB targeting arm that drives avidity. In the absence of FN-EDB the IL-12 stays masked; when FN-EDB is present it out-competes the cytokine and unveils it. Phage display and rational library design produced a lead switch arm (Switch2) binding IL-12 at 0.33 nM and FN-EDB at 250 nM, and cell assays confirmed FN-EDB-dependent IFN-gamma release from IL-12-receptor-bearing NK-92 cells.
What's novel
Most dual-Fab logic gates to date use cis-activation, where binding a receptor on a target cell unveils a ligand for a second receptor on the same cell. This is a trans-activation gate: activation is gated by a soluble/matrix antigen rather than a same-cell receptor, and a quantitative systems pharmacology model was used up front to define the binding affinities required for a positive therapeutic window before molecules were built.
Limitations
Efficacy is shown as in vitro IFN-gamma release and QSP-projected receptor occupancy, not in vivo tumor control; human IL-12 does not cross-react with the mouse receptor, so the team relied on modeling rather than mouse efficacy. In vitro FN-EDB concentrations were roughly 100-fold below tumor levels, and the higher-affinity switch arm only unmasked at elevated concentrations.
In context
It joins an active wave of conditionally activated cytokines and masked biologics aimed at widening the notoriously narrow IL-12 therapeutic window, and demonstrates QSP-guided antibody engineering, using a mechanistic model to set target affinities rather than screening blindly, which is increasingly how sophisticated switch molecules are designed.
Related tools on Ubi Biologics
- Target-Gated Cargo QSPmodel
A mechanistic QSP model for intravenously dosed biologics with tumour-enriched gating, the same trans-activation logic this switch implements.
Paper 3 · mAbs
Glycosylation penetrance of N-X-S/T sequons in antibody variable domains: a structural survey of 19,265 human antibody structures reassessing the histidine/glutamine suppression hypothesis
Across 19,265 antibody structures, variable-domain N-glycosylation shows up at only 7.82%, about half the rate from prior enriched datasets; glutamine at the sequon X-position is not a suppressor after all, and N-X-T sequons are 3.84-fold more likely to be glycosylated than N-X-S.
Core finding
A structural survey of 19,265 human antibody structures identified 1,368 N-X-S/T glycosylation sequons in variable domains and found N-glycosylation occupied at an observed penetrance of just 7.82% (107/1,368; Wilson 95% CI 6.5-9.4%), roughly half the 16.47% reported from an earlier glycosylation-enriched corpus. Occupancy depends sharply on the sequon's composition: histidine, lysine, and tryptophan at the X-position (the middle residue of N-X-S/T) showed zero observed glycosylation, and the third position matters too, with N-X-T sequons glycosylated 3.84-fold more often than N-X-S (13.64% vs 3.55%).
What's novel
The N-linked sequon is Asn-X-Ser/Thr, where X is any residue except proline and the enzyme oligosaccharyltransferase attaches glycan to the asparagine. Two long-standing design rules get corrected here. First, glutamine at the X-position was previously classified as a glycosylation suppressor, but with 6.45% penetrance (2/31) it is statistically indistinguishable from the 7.82% baseline, so the residues genuinely associated with suppression are histidine, lysine, and tryptophan, not glutamine. Second, the identity of the third residue is a strong, prior-stable effect: threonine-terminated sequons (N-X-T) are far more likely to actually be glycosylated than serine-terminated ones (N-X-S), so treating S and T as equivalent liabilities overcounts risk for N-X-S and undercounts it for N-X-T. The paper packages these into a sequence-only decision tree for triaging machine-designed antibody candidates.
Limitations
Crystallographic detection is a lower bound because disordered or unresolved glycans leave no density, so the true rate may be somewhat higher, and PDB deposition bias toward well-behaved, often non-glycosylated constructs likely persists even after correcting for the enriched corpus. The per-residue X-position counts are also small (for example only 31 glutamine sequons), so those specific estimates carry wide confidence intervals.
In context
As de novo and machine-learning antibody design pipelines (the paper explicitly targets tools like RFdiffusion) increasingly screen candidate sequences for developability liabilities up front, the sequon-occupancy priors those tools rely on matter directly; this recalibrates a widely used heuristic against a far larger structural evidence base and gives a concrete, position-aware triage rule rather than a flat flag on every sequon.
Related tools on Ubi Biologics
- AntPacktool
Numbers antibody domains and flags sequence liabilities, including the N-X-S/T sequons this dataset quantifies.
Paper 4 · Antibody Therapeutics
Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers
One antibody against the GI-cancer antigen CDH17 is deployed two ways, as an MMAE/MMAF ADC and as a bispecific engaging a rare pan-Vδ1/Vδ2 gamma-delta T-cell agonist nanobody, exploiting the abundance of gamma-delta T cells in gut epithelium.
Core finding
TAVO307, a monoclonal antibody binding CDH17 (cadherin-17) with picomolar affinity (46 pM by ELISA), was developed as complementary modalities. As an ADC with MMAF or MMAE payloads it killed GI cancer lines at 16.5-197 pM and inhibited xenograft growth 67-95%. Paired with VHH371, a rare pan-gamma-delta TCR agonist nanobody, it formed a T-cell engager that triggered gamma-delta T-cell degranulation against tumor cells, further boosted by an attenuated IL-15 fusion.
What's novel
VHH371 is an unusual antibody that activates both Vδ1 and Vδ2 gamma-delta T-cell subsets, addressing the subset heterogeneity that has limited gamma-delta cell therapy, and the work pairs that immune-engager modality with a cytotoxic ADC against the same GI-selective target, exploiting gamma-delta T cells' natural abundance in gut epithelium.
Limitations
All data are preclinical; the ADC's toxicity profile against normal intestinal epithelium is not yet established, IL-15/proliferation data come from limited PBMC donors, and the TCE shows a hook effect (loss of activity at high concentration) that will require careful dose optimization.
In context
CDH17 is an emerging GI-cancer target, and this positions two mechanistically distinct modalities against it at once; the pan-subset gamma-delta engager is notable amid broad current interest in gamma-delta T cells as an allogeneic, tissue-resident alternative to alpha-beta T-cell engagers.
Paper 5 · Clinical Cancer Research
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
A monovalent PD-1/CTLA-4 bispecific engineered to steer CTLA-4 blockade onto PD-1-positive T cells reported first-in-human data in 86 patients: 19.8% objective response, 17.5-month median duration, and T-cell activation beyond approved combination regimens.
Core finding
Volrustomig, an IgG1 monovalent bispecific that provides durable PD-1 blockade while preferentially engaging CTLA-4 on PD-1-positive T cells, was evaluated in a first-in-human phase 1 study (NCT03530397) across 2.25 to 2,500 mg IV every three weeks in patients with advanced solid tumors. Among 86 patients in the dose-exploration and immunotherapy-naive expansion cohorts, 17 (19.8%) had objective responses including 2 complete responses, with a median response duration of 17.5 months; at doses of 500 mg and above, the antibody drove peripheral and intratumoral T-cell activation exceeding that of approved PD-1/CTLA-4 regimens.
What's novel
The monovalent, preferential-engagement design aims to concentrate CTLA-4 blockade onto the already PD-1-engaged (exhausted, tumor-reactive) T-cell subset rather than blocking CTLA-4 systemically, an attempt to widen the therapeutic index relative to combining separate anti-PD-1 and anti-CTLA-4 antibodies.
Limitations
This is early dose-exploration and expansion data; efficacy signals are preliminary and uncontrolled, and long-term safety and durability of response are not yet established.
In context
Dual PD-1/CTLA-4 blockade is clinically validated but limited by the toxicity of free-combination checkpoint inhibition; volrustomig is one of several next-generation bispecific designs attempting to retain the efficacy of the combination while spatially restricting CTLA-4 engagement to lower systemic toxicity.
Paper 6 · Journal of Pharmacokinetics and Pharmacodynamics
QSP model for AAV-mediated antibody delivery in rat brain
A mechanistic model jointly tracks AAV vector, expressed antibody, target antigen, and antibody-target complex across brain subregions, predicting that intra-cisterna magna or intrastriatal delivery beats high-dose IV for CNS target engagement.
Core finding
A quantitative systems pharmacology model integrates AAV vector, brain, and monoclonal-antibody PBPK sub-models to track the vector, the antibody it expresses, the target antigen, and the antibody-target complex across plasma, peripheral tissue, and brain subregions (CSF and interstitial fluid). It predicts that intra-cisterna magna injection at a medium AAV dose, or intrastriatal injection at a low dose, achieves better CNS target engagement with less systemic exposure than high-dose intravenous administration of AAV encoding a CNS-targeted antibody.
What's novel
It is the first model to jointly describe vector, gene-delivered antibody, target, and complex disposition across brain subregions for AAV-delivered antibody therapeutics, a modality distinct from directly dosed antibodies and one that few PK/PD frameworks currently capture.
Limitations
It is built on rat data and a single undisclosed target/antibody system, so translation to human dosing carries substantial uncertainty, compounded by the known difficulty of projecting first-in-human AAV doses.
In context
As gene-delivered biologics for CNS disease advance, mechanistic models that connect route of administration to regional brain exposure become decision-support tools; this extends established antibody PBPK modeling to the added complexity of vector transduction and in situ antibody expression.
Related tools on Ubi Biologics
- Target-Gated Cargo QSPmodel
A mechanistic QSP model for dosed biologics, a structural reference for multi-compartment antibody distribution modelling.
Paper 7 · bioRxiv
Tuning the Structural Properties of a Single-Domain Antibody Scaffold for Improved Fibroblast Activation Protein Targeting
One anti-FAP nanobody engineered into three formats maps how valency and molecular weight trade off in PET imaging: the monomer clears fast, the low-MW bivalent dimer maximizes tumor-to-blood ratio, and the Fc-fusion gives the highest, most durable uptake.
Core finding
An affinity-matured anti-FAP VHH (F7) was built into a monomer, a low-molecular-weight tethered bivalent dimer (F7D), and an Fc-fusion (F7-Fc), with both bivalent constructs reaching picomolar affinity (29 pM and 38 pM by BLI). PET imaging in FAP-positive prostate cancer xenografts showed strongly format-dependent behavior: the monomer had rapid uptake and clearance with tumor uptake roughly two-fold above the small-molecule benchmark FAPI-46; F7D reached a tumor-to-blood ratio of about 4.3 at 24 hours; and F7-Fc gave the highest tumor uptake (roughly 10-15 %ID/g), enabling longitudinal imaging out to 144 hours with tumor-selective absorbed dose.
What's novel
It systematically compares valency and molecular-weight tuning within a single VHH binder against one target, directly mapping construct format to pharmacokinetic and imaging tradeoffs rather than reporting a single-format proof of concept, producing usable design rules for FAP-targeted theranostics.
Limitations
This is a preprint reporting preclinical imaging in one xenograft model; the monomer showed very high kidney retention (about 39 %ID/g), therapeutic (as opposed to imaging) payload data are not included, and human translation is untested.
In context
FAP is an attractive stromal target across solid tumors where small-molecule FAPI radiotracers suffer rapid washout; this shows camelid single-domain scaffolds can be format-tuned to trade clearance speed against tumor retention, informing the broader move toward biologic FAP radioligands.
Related tools on Ubi Biologics
- NbForgetool
Predicts nanobody structures with residue-level confidence for comparing the scaffold formats evaluated here.
Primary sources
- [1] Modular in vivo antibody–ADC click to reverse drug resistance in tumours (Nature)
- [2] Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate (mAbs)
- [3] Glycosylation penetrance of N-X-S/T sequons in antibody variable domains: a structural survey of 19,265 human antibody structures reassessing the histidine/glutamine suppression hypothesis (mAbs)
- [4] Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers (Antibody Therapeutics)
- [5] Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody (Clinical Cancer Research)
- [6] QSP model for AAV-mediated antibody delivery in rat brain (Journal of Pharmacokinetics and Pharmacodynamics)
- [7] Tuning the Structural Properties of a Single-Domain Antibody Scaffold for Improved Fibroblast Activation Protein Targeting (bioRxiv)